vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and CareTrust REIT, Inc. (CTRE). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $134.9M, roughly 1.0× CareTrust REIT, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 35.5%, a 47.0% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs 18.4%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
ADMA vs CTRE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $134.9M |
| Net Profit | $49.4M | $111.3M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | 82.5% |
| Revenue YoY | 18.4% | 55.1% |
| Net Profit YoY | -55.9% | 113.5% |
| EPS (diluted) | $0.20 | $0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $134.9M | ||
| Q3 25 | $134.2M | $132.4M | ||
| Q2 25 | $122.0M | $112.5M | ||
| Q1 25 | $114.8M | $96.6M | ||
| Q4 24 | $117.5M | $86.9M | ||
| Q3 24 | $119.8M | $77.4M | ||
| Q2 24 | $107.2M | $68.9M | ||
| Q1 24 | $81.9M | $63.1M |
| Q4 25 | $49.4M | $111.3M | ||
| Q3 25 | $36.4M | $74.9M | ||
| Q2 25 | $34.2M | $68.5M | ||
| Q1 25 | $26.9M | $65.8M | ||
| Q4 24 | $111.9M | $52.1M | ||
| Q3 24 | $35.9M | $33.4M | ||
| Q2 24 | $32.1M | $10.8M | ||
| Q1 24 | $17.8M | $28.7M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | — | ||
| Q3 25 | 38.0% | 58.1% | ||
| Q2 25 | 35.1% | 61.3% | ||
| Q1 25 | 30.4% | — | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | 43.0% | ||
| Q2 24 | 36.6% | 15.1% | ||
| Q1 24 | 26.7% | — |
| Q4 25 | 35.5% | 82.5% | ||
| Q3 25 | 27.1% | 56.6% | ||
| Q2 25 | 28.1% | 60.9% | ||
| Q1 25 | 23.4% | 68.1% | ||
| Q4 24 | 95.2% | 60.0% | ||
| Q3 24 | 30.0% | 43.2% | ||
| Q2 24 | 29.9% | 15.6% | ||
| Q1 24 | 21.7% | 45.6% |
| Q4 25 | $0.20 | $0.52 | ||
| Q3 25 | $0.15 | $0.35 | ||
| Q2 25 | $0.14 | $0.35 | ||
| Q1 25 | $0.11 | $0.35 | ||
| Q4 24 | $0.45 | $0.30 | ||
| Q3 24 | $0.15 | $0.21 | ||
| Q2 24 | $0.13 | $0.07 | ||
| Q1 24 | $0.08 | $0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $198.0M |
| Total DebtLower is stronger | $72.1M | $894.2M |
| Stockholders' EquityBook value | $477.3M | $4.0B |
| Total Assets | $624.2M | $5.1B |
| Debt / EquityLower = less leverage | 0.15× | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $198.0M | ||
| Q3 25 | $61.4M | $712.5M | ||
| Q2 25 | $90.3M | $306.1M | ||
| Q1 25 | $71.6M | $26.5M | ||
| Q4 24 | $103.1M | $213.8M | ||
| Q3 24 | $86.7M | $377.1M | ||
| Q2 24 | $88.2M | $495.1M | ||
| Q1 24 | $45.3M | $451.2M |
| Q4 25 | $72.1M | $894.2M | ||
| Q3 25 | $72.4M | $893.8M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $822.1M | ||
| Q4 24 | $72.3M | $396.9M | ||
| Q3 24 | — | $396.7M | ||
| Q2 24 | — | $671.1M | ||
| Q1 24 | — | $595.9M |
| Q4 25 | $477.3M | $4.0B | ||
| Q3 25 | $431.2M | $4.0B | ||
| Q2 25 | $398.3M | $3.3B | ||
| Q1 25 | $373.4M | $2.9B | ||
| Q4 24 | $349.0M | $2.9B | ||
| Q3 24 | $231.9M | $2.4B | ||
| Q2 24 | $188.3M | $1.9B | ||
| Q1 24 | $153.7M | $1.7B |
| Q4 25 | $624.2M | $5.1B | ||
| Q3 25 | $568.7M | $5.1B | ||
| Q2 25 | $558.4M | $4.7B | ||
| Q1 25 | $510.6M | $3.9B | ||
| Q4 24 | $488.7M | $3.4B | ||
| Q3 24 | $390.6M | $2.9B | ||
| Q2 24 | $376.4M | $2.7B | ||
| Q1 24 | $350.9M | $2.3B |
| Q4 25 | 0.15× | 0.22× | ||
| Q3 25 | 0.17× | 0.22× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | 0.21× | 0.14× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $394.0M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | 3.54× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $394.0M | ||
| Q3 25 | $13.3M | $100.9M | ||
| Q2 25 | $21.1M | $100.8M | ||
| Q1 25 | $-19.7M | $71.4M | ||
| Q4 24 | $50.2M | $244.3M | ||
| Q3 24 | $25.0M | $67.2M | ||
| Q2 24 | $45.6M | $53.0M | ||
| Q1 24 | $-2.2M | $48.8M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | 3.54× | ||
| Q3 25 | 0.36× | 1.35× | ||
| Q2 25 | 0.62× | 1.47× | ||
| Q1 25 | -0.73× | 1.08× | ||
| Q4 24 | 0.45× | 4.68× | ||
| Q3 24 | 0.70× | 2.01× | ||
| Q2 24 | 1.42× | 4.92× | ||
| Q1 24 | -0.12× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CTRE
Segment breakdown not available.
